General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2023-11-14 | 2023-09 | -2.15 | N/A | N/A | N/A |
2023-08-08 | 2023-06 | -2.88 | N/A | N/A | N/A |
2023-05-10 | 2023-03 | -2.34 | N/A | N/A | N/A |
2023-04-03 | 2022-12 | -2.21 | N/A | N/A | N/A |
2022-11-08 | 2022-09 | -2.35 | N/A | N/A | N/A |
2022-08-08 | 2022-06 | -1.9 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-07-06 | TD Cowen | Upgrade | Outperform | |
2023-06-29 | Ladenburg Thalmann | Upgrade | Buy | Buy |
2023-06-28 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-06-28 | Barclays | Upgrade | Overweight | Overweight |
2023-06-12 | SVB Leerink | Upgrade | Market Perform | Outperform |
2023-05-11 | Barclays | Upgrade | Overweight | Overweight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-06-13 | ANAND BHASKAR | Officer | 24.90K | Sale |
2023-07-05 | BIR DAWN CARTER | Officer | 35.01K | Stock Award(Grant) |
2023-06-06 | EDWARDS MARTIN | Director | 6.12K | Stock Award(Grant) |
2023-07-05 | HUFF JAMES WARREN | Chief Executive Officer | 132.88K | Stock Award(Grant) |
2023-06-06 | MCCLELLAN WILLIAM D JR | Director | 6.02K | Stock Award(Grant) |
2023-07-05 | MEYER COLIN JOHN | Officer | 84.37K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-03-30 | CPMG INC | 2.90M | 312.03M | 8.77% |
2023-03-30 | Vanguard Group, Inc. (The) | 2.75M | 296.30M | 8.33% |
2023-03-30 | Blackrock Inc. | 2.21M | 238.01M | 6.69% |
2023-03-30 | Perceptive Advisors Llc | 2.17M | 233.65M | 6.57% |
2023-03-30 | First Light Asset Management, LLC | 1.59M | 170.93M | 4.80% |
2023-03-30 | Deutsche Bank Aktiengesellschaft | 1.49M | 161.01M | 4.52% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-01-30 | Vanguard Specialized-Health Care Fund | 1.24M | 133.26M | 3.85% |
2022-12-30 | Vanguard Total Stock Market Index Fund | 822.63K | 88.61M | 2.56% |
2022-12-30 | Vanguard Small-Cap Index Fund | 694.86K | 74.84M | 2.16% |
2023-02-27 | iShares Russell 2000 ETF | 611.22K | 65.83M | 1.90% |
2022-12-30 | Vanguard Small Cap Value Index Fund | 486.87K | 52.44M | 1.52% |
2022-12-30 | Vanguard Extended Market Index Fund | 383.79K | 41.34M | 1.20% |
Yup, keep loading up on those puts.
Shorts need to cover after massive run up. It will ultimately trickle upwards towards 100
$RETA I finally will purchase a short position! This shits going down 30% tomorrow
So deals can be done behind the scenes at more favorable prices. You got a problem with that??
How this can go on is rediculous
Sorry for the delay, Jamie Dimon at JP Morgan is out back taking a shit. As soon as he’s done he’s going to approve a couple of trades and then we can turn this thing back on.
Funny, people looking for the news like that’s going to precede the stock price movement.
$RETA https://www.wvnews.com/news/around_the_web/amylyx-pharmaceuticals-announces-posting-of-briefing-documents-for-fda-advisory-committee-meeting-on-amx0035/article_4ed65042-b6ce-5be3-88d0-52cd175454b6.html
It’s tracking AMLX, following disappointing FDA notes.
$OBSV
Don’t mis this run. Lots of upside potential.
ObsEva SA (NASDAQ:OBSV) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Shareholders will be ecstatic, with their stake up 30% over the past week following ObsEva SA‘s (NASDAQ:OBSV) latest quarterly results. Revenues came in 113% better than analyst models expected, at US$4.0kwhile statutory losses per share were US$0.48, in line with forecasts. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.